Paso a Paso for Prediabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to refine a diabetes prevention program specifically for Spanish-speaking communities in Salt Lake City. It seeks to enhance the program's effectiveness and ease of implementation for individuals at high risk of developing type 2 diabetes. Participants will engage in a 12-month program called Paso a Paso, designed to help lower their diabetes risk. Native Spanish speakers living in the Wasatch Front area, with a BMI of 25 or higher, and at risk for diabetes based on a simple CDC test, might be suitable candidates for this trial. As an unphased trial, this study offers the opportunity to contribute to a program that could significantly benefit the community.
What prior data suggests that the Paso a Paso program is safe for participants?
Research has shown that the "Paso a Paso" program is being adjusted to meet the needs of Spanish-speaking communities. The program aims to help prevent diabetes in people at high risk. It is not a medication or a new medical treatment but a lifestyle program designed to reduce diabetes risk.
No information about side effects exists because the program focuses on education and lifestyle changes. It follows a method based on the National Diabetes Prevention Program, which has succeeded in other communities. As a customized and community-focused program, it is expected to be safe for participants.12345Why are researchers excited about this trial?
Researchers are excited about Paso a Paso because it offers a community-focused approach to tackling prediabetes, especially for Hispanic/Latino (H/L) communities at high risk for Type 2 Diabetes (T2D). Unlike standard treatments that often rely on medication or individual lifestyle changes, this program emphasizes group support and education within the community. This socially engaging method not only aims to reduce diabetes risk but also strengthens community ties, making it a unique and promising alternative to traditional care.
What evidence suggests that the Paso a Paso program might be an effective treatment for prediabetes?
Research has shown that programs tailored to the cultural needs of specific groups can effectively prevent type 2 diabetes (T2D) in high-risk individuals. The Paso a Paso program, which participants in this trial will engage in, targets Hispanic/Latino community members at high risk for T2D. Early results suggest that such programs help lower diabetes risk by promoting healthier habits. These programs emphasize activities like increasing physical activity and improving diet, which have proven to reduce the risk of developing diabetes. The cultural focus of the program is crucial because it addresses the community's specific needs, enhancing its relevance and usefulness.12467
Who Is on the Research Team?
Molly B Conroy, MD, MPH
Principal Investigator
University of Utah
Are You a Good Fit for This Trial?
This trial is for Spanish-speaking individuals at risk of diabetes, specifically those with impaired glucose tolerance or prediabetes. It aims to adapt and test the 'Paso a Paso' program tailored for their community needs.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Program Finalization and Instructor Training
Finalize the adapted 'Paso a Paso' protocol and materials, and train the first cohort of instructors
Intervention Implementation
Test the feasibility of the intervention implementation with 30 community participants
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Paso a Paso
Trial Overview
'Paso a Paso', an adapted version of the National Diabetes Prevention Program, is being tested for its feasibility in Spanish-speaking communities. The study will inform modifications needed for effective full-scale implementation.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Paso a Paso is a 12-month program designed for H/L community members who are at high risk for T2D and want to lower their risk.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Utah
Lead Sponsor
Citations
PASO A PASO: Tailored Diabetes Prevention Program for ...
Paso a Paso is a 12-month program designed for H/L community members who are at high risk for T2D and want to lower their risk. Cultural ...
2.
marlin-wrasse-gtkn.squarespace.com
marlin-wrasse-gtkn.squarespace.com/s/Clinical-Diabetes-Data-Brief-12052024-1.pdfClinical Diabetes Data Brief 12/05/2024
In El Paso, the prediabetes and type 2 diabetes population have a similar demographic spread, however, we find that females are more often ...
Comorbidity Prevalence in Prediabetes and Type 2 Diabetes
In this cross-sectional study, we analyzed data from 88,724 individuals diagnosed with type 2 diabetes and 12,071 individuals with prediabetes living in El Paso ...
4.
dshs.texas.gov
dshs.texas.gov/sites/default/files/legislative/2025-Reports/2025-texas-diabetes-council-assessment-report.pdf2025-texas-diabetes-council-assessment-report.pdf
7.1 million (34 percent) Texas adults have prediabetes.2 Prediabetes increases the likelihood of developing type 2 diabetes, heart disease, and stroke.3. 1 ...
A Culturally Tailored Physical Activity Intervention for Hispanic ...
The Salud Paso por Paso intervention is an effective way to promote PA in Hispanic adults living with T2DM. JMIR Diabetes 2025;10:e62876 doi: ...
Abstract P132
Abstract P132: Paso a Paso, Designing a Culturally Relevant Diabetes Prevention Intervention for Hispanic/Latino (H/L) People That Adheres ...
Abstract P132
This study uses a shared-leadership, community-engaged approach to develop a model for H/L T2D prevention based on DPP with members of the H/L community.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.